SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

ARV-6723

ARVN·Arvinas Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1/2
Time to market
At least several years. The drug is in Phase 1/2 dose-escalation with first patient dosed in September 2026. Initial clinical data is expected in H2 2027. If successful, a registrational trial and FDA review would follow, likely pushing potential approval into the 2030s.
Why 4/10
No PDUFA or pivotal readout is scheduled in the next ~12 months. The next catalyst is a preclinical data presentation at SITC 2026 (Nov 4-8, 2026), which is not a binary event. Initial clinical data is expected in H2 2027. ARV-6723 is one of several pipeline programs at Arvinas, limiting its individual share-price impact.
Actionable Insight NEUTRAL

ARV-6723 is in very early clinical development with no binary catalyst in the next 12 months. Watch for the SITC 2026 preclinical poster (Nov 4-8) and any early safety signals from the Phase 1 dose-escalation cohort. Initial clinical data is not expected until H2 2027. The drug is one of several pipeline assets at Arvinas, so its individual impact on the stock is limited in the near term.

Price Chart

Loading chart...

Executive Summary

ARV-6723 is Arvinas' first immuno-oncology candidate, an oral PROTAC drug designed to degrade HPK1, a protein that suppresses immune activity against tumors. It entered a Phase 1/2 first-in-human clinical trial (NCT07749586) in September 2026 for advanced solid tumors, both as a monotherapy and in combination with pembrolizumab. Preclinical data showed robust single-agent antitumor activity superior to checkpoint inhibitors in animal models. However, the drug is at a very early stage with no clinical data yet; initial results are not expected until the second half of 2027. Arvinas has a $558.9M cash runway into H2 2028 and a diversified pipeline, but the stock trades near its 52-week low of $6.74 with mixed institutional signals.

How It Works

ARV-6723 is an oral drug that uses PROTAC technology to seek out and destroy a protein called HPK1 inside immune cells. HPK1 normally acts as a brake on the immune system's ability to attack cancer. By degrading HPK1, ARV-6723 aims to release the brakes on T cells and other immune cells, helping them recognize and kill tumor cells. It is being tested both alone and in combination with the checkpoint inhibitor pembrolizumab (Keytruda).

Trial Status

The Phase 1/2 first-in-human trial (NCT07749586) began dosing in September 2026 and is currently recruiting patients with advanced solid tumors. The trial is evaluating oral ARV-6723 as monotherapy and in combination with pembrolizumab. The monotherapy dose-escalation cohort has been initiated. Preclinical data was presented at AACR 2026 and will be presented at SITC 2026 (Nov 4-8).

The Two-Sided Case

▲ Bull Case5
Preclinical data showed ARV-6723 as a monotherapy demonstrated superior antitumor activity compared to anti-PD-1 antibodies and an investigational HPK1 inhibitor across multiple solid tumor models, including checkpoint-resistant models.
ARV-6723 is the first HPK1 PROTAC degrader to enter clinical trials in the United States, and its degradation mechanism may offer advantages over traditional kinase inhibitors by also disrupting HPK1's scaffolding functions.
Arvinas has a strong cash position of $558.9M with runway into H2 2028, sufficient to fund multiple clinical programs including ARV-6723 through initial data readouts.
Analyst consensus is bullish: 13 Buy/Strong Buy ratings vs 1 Sell, with a mean price target of $14.54 (93.3% implied upside from the current $7.52 close).
The company plans to present new preclinical data at SITC 2026 (Nov 4-8) demonstrating ARV-6723's activity in checkpoint-resistant models, which could generate positive sentiment.
▼ Bear Case5
ARV-6723 is in a Phase 1/2 first-in-human trial with no clinical efficacy or safety data yet; early-stage oncology drugs have a high failure rate.
HPK1 is a competitive target with several small-molecule inhibitors already in clinical trials from other developers, creating a crowded field.
The stock trades at $7.09, down ~5.7% on Q3 earnings day, and has a 52-week low of $6.74, indicating persistent selling pressure.
Several large institutional holders trimmed or exited positions in Q2 2026, including Citadel (-47%), Morgan Stanley (-26%), and JPMorgan (-78%).
Arvinas has multiple pipeline programs (ARV-393, ARV-027, ARV-102, ARV-806) competing for capital, and ARV-6723 is the earliest-stage among them.

Upcoming Catalysts

  • SITC 2026 Annual Meeting (Nov 4-8, 2026): New preclinical data demonstrating ARV-6723's activity in checkpoint-resistant models.
  • Initial Phase 1 clinical data expected in H2 2027.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Arvinas Inc. PRESS-RELEASE ARVN ·Originating report

Sources · 12

Hover a chip for the title
1 arvinas.com2 arvinas.com3 ir.arvinas.com4 biospace.com5 biospace.com6 arvinas.b-cdn.net7 synapse.patsnap.com8 ventures.yale.edu9 fool.com10 clinicaltrials.gov11 markets.businessinsider.com12 tradingkey.com